WATERTOWN, Mass.--(BUSINESS WIRE)--
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the
development of RNAi-based therapeutics, today announced the appointment
of Pankaj Bhargava, M.D., as Chief Medical Officer. Dr. Bhargava brings
to Dicerna more than 15 years of experience in oncology drug development
and translational research gained in leading industry and academic
institutions. In his role as Chief Medical Officer, he will be
responsible for clinical development activities as well as regulatory
"Pankaj is the ideal person to lead our clinical and regulatory team as
we advance DCR-M1711 into the clinic," said Douglas M. Fambrough, Ph.D.,
Chief Executive Officer of Dicerna. "His direct experience in clinical
development, medical affairs and regulatory strategy, and his
interactions with FDA and EMA will be of high value to us for both our
indications in oncology and rare genetic diseases that we can target
through the liver. I am thrilled to welcome Pankaj to Dicerna's
Prior to joining Dicerna, Dr. Bhargava was Associate Vice President at
Sanofi Oncology, where he led the global development of aflibercept
(ZALTRAP™) culminating in successful approvals by U.S. Food and Drug
Administration (FDA), European Medicines Agency (EMA) and several
regulatory authorities worldwide. Prior to Sanofi, Dr. Bhargava was Vice
President Clinical Research and Interim Chief Medical Officer at AVEO
Pharmaceuticals where he oversaw the development of all of the company's
clinical programs. Since October 2004, Dr. Bhargava has served as an
attending physician at the Dana-Farber Cancer Institute and a faculty
member at Harvard Medical School.
Dr. Bhargava received his medical degree from University College of
Medical Sciences, Delhi University, India in 1991. He completed his
residency in Internal Medicine at the Maimonides Medical Center,
SUNY-Brooklyn and fellowships in both Medical Oncology and Clinical
Pharmacology at Georgetown University. Dr. Bhargava also served as
co-director of the Gastrointestinal Oncology Program at University of
Massachusetts Medical Center in Worcester.
About Dicerna Pharmaceuticals, Inc.
Dicerna is a biopharmaceutical company focused on the discovery and
development of innovative treatments for rare inherited diseases
involving the liver and for cancers that are genetically defined.
Dicerna is using its proprietary RNA interference (RNAi) technology
platform to build a broad pipeline in these therapeutic areas and
intends to discover, develop and commercialize novel therapeutics either
on its own or in collaboration with pharmaceutical partners.
Cautionary Note on Forward-Looking Statements
This press release includes forward-looking statements. Such
forward-looking statements are subject to risks and uncertainties that
could cause actual results to differ materially from those expressed or
implied in such statements. Applicable risks and uncertainties include
those identified under the heading "Risk Factors" included in the
prospectus related to the initial public offering, and in other filings
that Dicerna may make with the SEC in the future. The forward-looking
statements contained in this press release reflect Dicerna's current
views with respect to future events, and Dicerna does not undertake and
specifically disclaims any obligation to update any forward-looking
Dicerna Pharmaceuticals, Inc.
James B. Weissman,
Chief Business Officer
Chris Erdman, 781-235-3060
Source: Dicerna Pharmaceuticals, Inc.
News Provided by Acquire Media